Form 4: Corvus Pharmaceuticals Director Scott Morrison Granted 15,000 Stock Options

Corvus Pharmaceuticals, Inc. Director Scott W. Morrison was granted 15,000 stock options with an exercise price of $4.24, vesting over one year or by the 2026 Annual Meeting.

Summary

• Scott W. Morrison, a Director of Corvus Pharmaceuticals, Inc. (CRVS), was granted 15,000 stock options.
• The transaction date for this grant was June 12, 2025.
• Each stock option has an exercise price of $4.24.
• The options are exercisable for 15,000 shares of Corvus Pharmaceuticals Common Stock.
• The options vest and become exercisable as to 100% of the total number of shares on the earlier of the first anniversary of the grant date (June 12, 2026) or the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service.
• The expiration date for these stock options is June 12, 2035.

Sentiment

Score: 7

Explanation: The document reports a routine equity compensation event for a director, which is generally viewed as neutral to slightly positive as it aligns the director's interests with the company's long-term performance.

Positives

• The grant of stock options to a director aligns their financial interests with the long-term performance and shareholder value creation of Corvus Pharmaceuticals.
• This is a standard form of equity compensation, indicating continued commitment from the director.

Future Outlook

The stock options are subject to a vesting schedule, requiring continuous service as a director until the earlier of the first anniversary of the grant date or the 2026 Annual Meeting, indicating an expectation of continued tenure and alignment with future company performance.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, serving as a key component of executive and director compensation packages to incentivize long-term value creation and retain talent.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• While specific comparable companies or projects are not detailed in this filing, such equity grants are typically benchmarked against peer groups in terms of size and vesting conditions to ensure competitive compensation and alignment with shareholder interests.

Related Party Transactions

• The grant of stock options to Scott W. Morrison, a Director of Corvus Pharmaceuticals, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with shareholder interests, potentially encouraging decisions that enhance long-term stock value.
• Employees: While not directly impacting general employees, such compensation practices can influence overall corporate culture and compensation philosophy.

Next Steps

• The stock options will vest on the earlier of June 12, 2026, or the date of the 2026 Annual Meeting of Stockholders, assuming continuous service.
• Upon vesting, the director will have the right to exercise the options to acquire common stock at the specified exercise price.

Key Dates

Keywords

Corvus Pharmaceuticals, CRVS, Stock Options, Director Compensation, Equity Grant, SEC Form 4, Insider Transaction, Beneficial Ownership